ClinicalTrials.gg
CompletedNCT01951586Updated Oct 25, 2021Results posted

Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer

A Phase 2 interventional study of Denosumab and Zoledronic acid in Non-Small Cell Lung Cancer, sponsored by Amgen. Completed at 74 sites in 10 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2021-10-25.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
226
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Carcinoma, Non-Small-Cell Lung by Amgen — 2 open to participants now, 7 under way, 4 of them phase 3. Carcinoma, Non-Small-Cell Lung · Amgen.

Enrollment
9th of 31
226 · median 145
Started
2013
with 1 other
Phase 2
14 of 40
none open now
Registered
23rd of 40
by date

Among the 40 studies in Carcinoma, Non-Small-Cell Lung by Amgen, this one is the 9th largest by enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2013, is one of 14 in phase 2, and was the 23rd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

2 of the 40 studies in Carcinoma, Non-Small-Cell Lung by Amgen are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Carcinoma, Non-Small-Cell Lung by Amgen, or all of them as a file.
02

Study summary

This randomized phase 2 trial is studying the effect of adding denosumab to standard chemotherapy in the treatment of advanced lung cancer.

Read the detailed description

This is a global randomized double-blind placebo-controlled study in patients with Stage IV untreated non-small cell lung cancer (NSCLC) with or without bone metastasis. Eligible participants are to receive 4 to 6 cycles of a standard of care platinum-doublet chemotherapy regimen. Participants will be randomized in a 2:1 ratio to receive denosumab or matching placebo with the first investigational product dose coinciding with participant's first cycle of chemotherapy and continuing until the primary analysis, unacceptable toxicity, withdrawal of consent, death, or lost to follow-up. Participants who discontinued the investigational product early (ie, before primary analysis) were followed for disease status and survival. The primary analysis took place when 149 events of death had been reported. All participants were followed for 2 years after the last dose of blinded investigational product.

03

Conditions studied

  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed stage IV non-small cell lung carcinoma (NSCLC), according to 7th Tumor/Node/ (TNM) classification (cytological specimens obtained by bronchial washing or brushing, or fine-needle aspiration are acceptable)
  • Subject has available and has provided consent to release to the sponsor (or designee) a tumor block with confirmed tumor content (or approximately 20 unstained charged slides [a minimum of 7 slides is mandatory]) and the corresponding pathology report
  • Planned to receive 4 to 6 cycles of pemetrexed or gemcitabine in combination with cisplatin or carboplatin

    • For subjects to receive pemetrexed, planned to receive vitamin B12 and folate per pemetrexed approved labeling
  • Radiographically evaluable (measurable or non-measurable) disease (according to modified (RECIST) 1.1 criteria
  • Other inclusion criteria may apply

Exclusion criteria

Exclusion Criteria:

  • Known presence of documented sensitizing epidermal growth factor receptor (EGFR) activating mutation or echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) translocation (screening following local standards, but strongly encouraged in non-squamous histology)
  • Known (systematic screening of patients not mandatory)
  • Any prior systemic therapy (before randomization) for the treatment of NSCLC (including chemoradiation), except if for non- disease and was completed at least 6 months prior to randomization
  • Planned to receive bevacizumab
  • Significant dental/oral disease, including prior history or current evidence of osteonecrosis/ osteomyelitis of the jaw, or with the following:

    • Active dental or jaw condition which requires oral surgery
    • Non-healed dental/oral surgery
    • Planned invasive dental procedures for the course of the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
226 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo matching to denosumab by subcutaneous injection once every 4 weeks plus one loading dose on study day 8 in addition to platinum-based standard chemotherapy. Participants with bone metastases also received 4 mg zoledronic acid administered as an IV infusion Q4W or Q3W.

    Drug: Zoledronic acid · Drug: Placebo to Denosumab · Drug: Standard Chemotherapy

  • Experimental
    Denosumab

    Participants received 120 mg denosumab by subcutaneous injection once every 4 weeks plus one loading dose on study day 8 in addition to platinum-based standard chemotherapy. Participants with bone metastases also received placebo to zoledronic acid administered as an IV infusion Q4W or Q3W.

    Drug: Denosumab · Drug: Standard Chemotherapy · Drug: Placebo to Zoledronic Acid

Interventions

  • Administered by subcutaneous injection once every 4 weeks (Q4W) plus one loading dose on study day 8; could be administered as often as every 3 weeks (Q3W) to participants receiving Q3W chemotherapy.

    Also known as: XGEVA

  • DrugZoledronic acid

    Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.

    Also known as: Zometa

  • DrugPlacebo to Denosumab

    Administered by subcutaneous injection once every 4 weeks (Q4W) plus one loading dose on study day 8; could be administered as often as every 3 weeks (Q3W) to participants receiving Q3W chemotherapy.

  • DrugStandard Chemotherapy

    Standard of care chemotherapy consisting of pemetrexed or gemcitabine in combination with cisplatin or carboplatin administered according to local practice.

  • DrugPlacebo to Zoledronic Acid

    Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Overall survival was calculated as the time from the date of randomization to the date of death from any cause. Participants last known to be alive were censored at the last contact date.

    Time frame: From randomization until the end of study; median time on study was 9.64 months.

Secondary outcomes

  1. Correlation of Tumor Tissue RANK Expression With Overall Survival

    To assess whether the treatment effect on overall survival was correlated with receptor activator of nuclear factor (NF)-κB (RANK) protein expression in tumor cells, RANK expression in archival tumor samples was measured using immunohistochemistry. The intensity of stain in the cytoplasm, membrane, and total was categorized as 0 (negative), 1+ (weak), 2+ (moderate) or 3+ (strong); All intensity is the sum of levels +1, +2 and +3. In addition, an H-score was calculated using the following formula: H-score=(percentage of cells of weak×1)+(percentage of cells of moderate×2)+(percentage of cells of strong×3). The maximum H-score was 300, corresponding to 100% of cells with strong intensity. The correlation between RANK expression level and OS was evaluated using a Cox proportional hazard models that included RANK expression level stratified by the randomization stratification factors in the corresponding treatment group.

    Time frame: From randomization until the data cut-off date of 29 July 2016; median time on study was 9.64 months.

  2. Correlation of Tumor Tissue RANK Ligand Expression With Overall Survival

    To assess whether the treatment effect on overall survival was correlated with RANK ligand (RANKL) protein expression in tumor cells, RANKL expression in archival tumor samples was measured using immunohistochemistry. The intensity of stain in the cytoplasm was categorized as 0 (negative), 1+ (weak), 2+ (moderate) or 3+ (strong); All intensity is the sum of levels +1, +2 and +3. In addition, an H-score was calculated using the following formula: H-score=(percentage of cells of weak×1)+(percentage of cells of moderate×2)+(percentage of cells of strong×3). The maximum H-score was 300, corresponding to 100% of cells with strong intensity. The correlation between RANKL expression level and OS was evaluated using a Cox proportional hazard models that included RANKL expression level stratified by the randomization stratification factors in the corresponding treatment group.

    Time frame: From randomization until the data cut-off date of 29 July 2016; median time on study was 9.64 months.

  3. Objective Response Rate

    Objective response rate was defined as the percentage of participants with a complete response (CR) or partial response (PR) based on modified RECIST 1.1 achieved over the study duration. CR: Disappearance of all target and non target lesions, normalization of tumor marker levels and no new lesions. PR: At least a 30% decrease in the size of target lesions with no progression of non-target lesions and no new lesions, or, disappearance of target lesions with persistence of one or more non-target lesions and/or maintenance of tumor marker levels above normal limits and no new lesions. Participants who underwent surgical resection while on study were not evaluated for response after the surgery. Participants who did not meet the criteria for an objective response by the analysis cutoff date were considered non-responders.

    Time frame: From randomization until the data cut-off date of 29 July 2016; median time on study was 9.64 months.

  4. Correlation of Tumor Tissue RANK Expression With Objective Response Rate

    To assess whether the treatment effect on objective response rate (ORR) based on RECIST 1.1 was correlated with RANK protein expression in tumor cells, RANK expression in archival tumor samples was measured using immunohistochemistry. The intensity of stain in the cytoplasm, membrane, and total was categorized as 0 (negative), 1+ (weak), 2+ (moderate) or 3+ (strong); All intensity is the sum of levels +1, +2 and +3. In addition, an H-score was calculated using the following formula: H-score=(percentage of cells of weak×1)+(percentage of cells of moderate×2)+(percentage of cells of strong×3). The maximum H-score was 300, corresponding to 100% of cells with strong intensity. The correlation between RANK expression level and ORR was evaluated within each treatment group using a logistical regression model that included RANK expression value as an independent variable and stratified by the randomization stratification factors. The odds ratio and 95% confidence interval are reported.

    Time frame: From randomization until the data cut-off date of 29 July 2016; median time on study was 9.64 months.

  5. Correlation of Tumor Tissue RANKL Expression With Objective Response Rate

    To assess whether the treatment effect on objective response rate (ORR) based on RECIST 1.1 was correlated with RANKL protein expression in tumor cells, RANKL expression in archival tumor samples was measured using immunohistochemistry. The intensity of stain in the cytoplasm was categorized as 0 (negative), 1+ (weak), 2+ (moderate) or 3+ (strong); All intensity is the sum of levels +1, +2 and +3. In addition, an H-score was calculated using the following formula: H-score=(percentage of cells of weak×1)+(percentage of cells of moderate×2)+(percentage of cells of strong×3). The maximum H-score was 300, corresponding to 100% of cells with strong intensity. The correlation between RANKL expression level and ORR was evaluated within each treatment group using a logistical regression model that included RANKL expression value as an independent variable and stratified by the randomization stratification factors. The odds ratio and 95% confidence interval are reported.

    Time frame: From randomization until the data cut-off date of 29 July 2016; median time on study was 9.64 months.

  6. Clinical Benefit Rate

    Clinical benefit rate was defined as the percentage of participants with an objective response (CR or PR) or stable disease (SD) or better for at least 16 weeks achieved over the study duration. If a participant underwent surgical resection while on study, the participant was not evaluated for response after the surgery. Participants who did not meet the criteria for clinical benefit by the analysis cutoff date were considered as non-responders.

    Time frame: From randomization until the data cut-off date of 29 July 2016; median time on study was 9.64 months.

  7. Progression-free Survival (PFS)

    Progression-free survival was defined as the time from randomization to the first observed disease progression per modified RECIST 1.1 criteria or death from any cause. Participants last known to be alive who did not experience disease progression were censored at their last imaging assessment date, last contact date if they were in the survival follow up phase, end of the study date, or the primary analysis cut-off date, whichever was first. If a participant underwent surgical resection while on study, the participant was censored at the last evaluable imaging assessment prior to the surgery.

    Time frame: From randomization until the data cut-off date of 29 July 2016; median time on study was 9.64 months.

  8. Serum Denosumab Trough Levels in Participants Who Received Q3W Dosing

    Serum samples were analyzed for denosumab using enzyme-linked immunosorbent assay (ELISA) following a validated procedure. The lower limit of quantification for the assay was 20 ng/mL.

    Time frame: Prior to dosing at day 8 and weeks 3, 6, 9, 12, 15, 18, 21 and 24.

  9. Serum Denosumab Trough Levels in Participants Who Received Q4W Dosing

    Serum samples were analyzed for denosumab using enzyme-linked immunosorbent assay (ELISA) following a validated procedure. The lower limit of quantification for the assay was 20 ng/mL.

    Time frame: Prior to dosing at day 8 and weeks 4, 8, 12, 16, 20 and 24

  10. Number of Participants With Treatment-emergent Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant. The event does not necessarily have a causal relationship with study treatment. A serious adverse event is defined as an AE that meets at least 1 of the following criteria * fatal * life threatening * requires in-patient hospitalization or prolongation of existing hospitalization * results in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event Treatment-related AEs include only TEAEs for which the investigator indicated there was a reasonable possibility they may have been caused by study drug. Fatal adverse events include only deaths reported on the Adverse Event Case Report Form.

    Time frame: From first dose of study drug to the end of study date; the median (min, max) duration was 10.0 (0.2, 41.4) and 9.4 (0.2, 42.9) months for Placebo and Denosumab respectively.

07

Results

Posted Aug 28, 2017

Participant flow

This study was conducted at 57 centers in 10 countries including the United Kingdom, Netherlands, France, Italy, Germany, Czech Republic, United States, Canada, Australia and Greece. Participants were enrolled from 31 December 2013 to 21 May 2015.

Participant flow — Overall Study
MilestonePlaceboDenosumab
Started78148
Received study drug76145
Completed00
Not completed78148
Withdrew: Death61120
Withdrew: Withdrawal by subject817
Withdrew: Lost to follow-up01
Withdrew: Sponsor decision910

Outcome measures

PrimaryOverall Survival (OS)

Overall survival was calculated as the time from the date of randomization to the date of death from any cause. Participants last known to be alive were censored at the last contact date.

Time frame:
From randomization until the end of study; median time on study was 9.64 months.
Reported as:
Median · months
Overall Survival (OS)
monthsPlaceboDenosumab
Overall Survival (OS)10.9 (9.26 to 15.54)10.7 (8.54 to 12.35)
Statistical analysis
  • Placebo vs Denosumab · Log Rank · p = 0.5157 · Hazard ratio (hr): 1.11 · 95% CI 0.81 to 1.53Based on a Cox proportional hazards model stratified by the randomized stratification factors. Hazard ratio \< 1 favors denosumab.
SecondaryCorrelation of Tumor Tissue RANK Expression With Overall Survival

To assess whether the treatment effect on overall survival was correlated with receptor activator of nuclear factor (NF)-κB (RANK) protein expression in tumor cells, RANK expression in archival tumor samples was measured using immunohistochemistry. The intensity of stain in the cytoplasm, membrane, and total was categorized as 0 (negative), 1+ (weak), 2+ (moderate) or 3+ (strong); All intensity is the sum of levels +1, +2 and +3. In addition, an H-score was calculated using the following formula: H-score=(percentage of cells of weak×1)+(percentage of cells of moderate×2)+(percentage of cells of strong×3). The maximum H-score was 300, corresponding to 100% of cells with strong intensity. The correlation between RANK expression level and OS was evaluated using a Cox proportional hazard models that included RANK expression level stratified by the randomization stratification factors in the corresponding treatment group.

Time frame:
From randomization until the data cut-off date of 29 July 2016; median time on study was 9.64 months.
Reported as:
Number · hazard ratio
Correlation of Tumor Tissue RANK Expression With Overall Survival
hazard ratioPlaceboDenosumab
Cytoplasm all intensity0.84 (0.65 to 1.09)1.00 (0.85 to 1.17)
Membrane all intensity0.72 (0.51 to 1.01)0.92 (0.74 to 1.14)
Total all intensity0.80 (0.62 to 1.03)1.00 (0.85 to 1.17)
Cytoplasm H-score0.83 (0.65 to 1.07)1.00 (0.86 to 1.16)
Membrane H-score0.72 (0.52 to 1.00)0.93 (0.77 to 1.13)
Total H-score0.80 (0.62 to 1.02)1.00 (0.86 to 1.16)
Statistical analysis
  • Placebo vs Denosumab · Cox propotional hazard model · p = 0.3759
  • Placebo vs Denosumab · Cox propotional hazard model · p = 0.3666
  • Placebo vs Denosumab · Cox propotional hazard model · p = 0.1917
  • Placebo vs Denosumab · Cox propotional hazard model · p = 0.3353
  • Placebo vs Denosumab · Cox propotional hazard model · p = 0.3179
  • Placebo vs Denosumab · Cox propotional hazard model · p = 0.1583
SecondaryCorrelation of Tumor Tissue RANK Ligand Expression With Overall Survival

To assess whether the treatment effect on overall survival was correlated with RANK ligand (RANKL) protein expression in tumor cells, RANKL expression in archival tumor samples was measured using immunohistochemistry. The intensity of stain in the cytoplasm was categorized as 0 (negative), 1+ (weak), 2+ (moderate) or 3+ (strong); All intensity is the sum of levels +1, +2 and +3. In addition, an H-score was calculated using the following formula: H-score=(percentage of cells of weak×1)+(percentage of cells of moderate×2)+(percentage of cells of strong×3). The maximum H-score was 300, corresponding to 100% of cells with strong intensity. The correlation between RANKL expression level and OS was evaluated using a Cox proportional hazard models that included RANKL expression level stratified by the randomization stratification factors in the corresponding treatment group.

Time frame:
From randomization until the data cut-off date of 29 July 2016; median time on study was 9.64 months.
Reported as:
Number · hazard ratio
Correlation of Tumor Tissue RANK Ligand Expression With Overall Survival
hazard ratioPlaceboDenosumab
Cytoplasm all intensity0.77 (0.63 to 0.95)0.93 (0.82 to 1.05)
Cytoplasm H-score0.79 (0.66 to 0.95)0.93 (0.84 to 1.04)
Statistical analysis
  • Placebo vs Denosumab · Cox propotional hazard model · p = 0.3946
  • Placebo vs Denosumab · Cox propotional hazard model · p = 0.3735
SecondaryObjective Response Rate

Objective response rate was defined as the percentage of participants with a complete response (CR) or partial response (PR) based on modified RECIST 1.1 achieved over the study duration. CR: Disappearance of all target and non target lesions, normalization of tumor marker levels and no new lesions. PR: At least a 30% decrease in the size of target lesions with no progression of non-target lesions and no new lesions, or, disappearance of target lesions with persistence of one or more non-target lesions and/or maintenance of tumor marker levels above normal limits and no new lesions. Participants who underwent surgical resection while on study were not evaluated for response after the surgery. Participants who did not meet the criteria for an objective response by the analysis cutoff date were considered non-responders.

Time frame:
From randomization until the data cut-off date of 29 July 2016; median time on study was 9.64 months.
Reported as:
Number · percentage of participants
Objective Response Rate
percentage of participantsPlaceboDenosumab
Objective Response Rate43.436.8
Statistical analysis
  • Placebo vs Denosumab · Regression, Logistic · p = 0.3491 · Odds ratio (or): 0.76 · 95% CI 0.43 to 1.35Based on a logistic regression model adjusted for the randomization stratification factors; an odds ratio ≥ 1 favors denosumab.
SecondaryCorrelation of Tumor Tissue RANK Expression With Objective Response Rate

To assess whether the treatment effect on objective response rate (ORR) based on RECIST 1.1 was correlated with RANK protein expression in tumor cells, RANK expression in archival tumor samples was measured using immunohistochemistry. The intensity of stain in the cytoplasm, membrane, and total was categorized as 0 (negative), 1+ (weak), 2+ (moderate) or 3+ (strong); All intensity is the sum of levels +1, +2 and +3. In addition, an H-score was calculated using the following formula: H-score=(percentage of cells of weak×1)+(percentage of cells of moderate×2)+(percentage of cells of strong×3). The maximum H-score was 300, corresponding to 100% of cells with strong intensity. The correlation between RANK expression level and ORR was evaluated within each treatment group using a logistical regression model that included RANK expression value as an independent variable and stratified by the randomization stratification factors. The odds ratio and 95% confidence interval are reported.

Time frame:
From randomization until the data cut-off date of 29 July 2016; median time on study was 9.64 months.
Reported as:
Number · odds ratio
Correlation of Tumor Tissue RANK Expression With Objective Response Rate
odds ratioPlaceboDenosumab
Cytoplasm all intensity1.00 (0.67 to 1.50)0.88 (0.68 to 1.13)
Membrane all intensity1.18 (0.74 to 1.89)0.82 (0.57 to 1.17)
Total all intensity1.16 (0.78 to 1.71)0.88 (0.68 to 1.13)
Cytoplasm H-score1.00 (0.69 to 1.47)0.87 (0.68 to 1.11)
Membrane H-score1.14 (0.74 to 1.76)0.82 (0.59 to 1.14)
Total H-score1.14 (0.79 to 1.65)0.87 (0.69 to 1.11)
Statistical analysis
  • Placebo vs Denosumab · Regression, Logistic · p = 0.4760
  • Placebo vs Denosumab · Regression, Logistic · p = 0.2582
  • Placebo vs Denosumab · Regression, Logistic · p = 0.2230
  • Placebo vs Denosumab · Regression, Logistic · p = 0.4329
  • Placebo vs Denosumab · Regression, Logistic · p = 0.2620
  • Placebo vs Denosumab · Regression, Logistic · p = 0.2081
SecondaryCorrelation of Tumor Tissue RANKL Expression With Objective Response Rate

To assess whether the treatment effect on objective response rate (ORR) based on RECIST 1.1 was correlated with RANKL protein expression in tumor cells, RANKL expression in archival tumor samples was measured using immunohistochemistry. The intensity of stain in the cytoplasm was categorized as 0 (negative), 1+ (weak), 2+ (moderate) or 3+ (strong); All intensity is the sum of levels +1, +2 and +3. In addition, an H-score was calculated using the following formula: H-score=(percentage of cells of weak×1)+(percentage of cells of moderate×2)+(percentage of cells of strong×3). The maximum H-score was 300, corresponding to 100% of cells with strong intensity. The correlation between RANKL expression level and ORR was evaluated within each treatment group using a logistical regression model that included RANKL expression value as an independent variable and stratified by the randomization stratification factors. The odds ratio and 95% confidence interval are reported.

Time frame:
From randomization until the data cut-off date of 29 July 2016; median time on study was 9.64 months.
Reported as:
Number · odds ratio
Correlation of Tumor Tissue RANKL Expression With Objective Response Rate
odds ratioPlaceboDenosumab
Cytoplasm all intensity1.27 (0.88 to 1.83)1.10 (0.90 to 1.35)
Cytoplasm H-score1.25 (0.91 to 1.72)1.09 (0.91 to 1.30)
Statistical analysis
  • Placebo vs Denosumab · Regression, Logistic · p = 0.4671
  • Placebo vs Denosumab · Regression, Logistic · p = 0.4236
SecondaryClinical Benefit Rate

Clinical benefit rate was defined as the percentage of participants with an objective response (CR or PR) or stable disease (SD) or better for at least 16 weeks achieved over the study duration. If a participant underwent surgical resection while on study, the participant was not evaluated for response after the surgery. Participants who did not meet the criteria for clinical benefit by the analysis cutoff date were considered as non-responders.

Time frame:
From randomization until the data cut-off date of 29 July 2016; median time on study was 9.64 months.
Reported as:
Number · percentage of participants
Clinical Benefit Rate
percentage of participantsPlaceboDenosumab
Clinical Benefit Rate53.947.9
Statistical analysis
  • Placebo vs Denosumab · Regression, Logistic · p = 0.4654 · Odds ratio (or): 0.81 · 95% CI 0.46 to 1.43Based on a logistic regression model adjusted for the randomization stratification factors; an odds ratio ≥ 1 favors denosumab.
SecondaryProgression-free Survival (PFS)

Progression-free survival was defined as the time from randomization to the first observed disease progression per modified RECIST 1.1 criteria or death from any cause. Participants last known to be alive who did not experience disease progression were censored at their last imaging assessment date, last contact date if they were in the survival follow up phase, end of the study date, or the primary analysis cut-off date, whichever was first. If a participant underwent surgical resection while on study, the participant was censored at the last evaluable imaging assessment prior to the surgery.

Time frame:
From randomization until the data cut-off date of 29 July 2016; median time on study was 9.64 months.
Reported as:
Median · months
Progression-free Survival (PFS)
monthsPlaceboDenosumab
Progression-free Survival (PFS)5.7 (4.37 to 7.16)5.2 (4.24 to 5.78)
Statistical analysis
  • Placebo vs Denosumab · Log Rank · p = 0.7363 · Hazard ratio (hr): 1.05 · 95% CI 0.78 to 1.43Based on a Cox proportional hazards model stratified by the randomized stratification factors. Hazard ratio \< 1 favors denosumab.
SecondarySerum Denosumab Trough Levels in Participants Who Received Q3W Dosing

Serum samples were analyzed for denosumab using enzyme-linked immunosorbent assay (ELISA) following a validated procedure. The lower limit of quantification for the assay was 20 ng/mL.

Time frame:
Prior to dosing at day 8 and weeks 3, 6, 9, 12, 15, 18, 21 and 24.
Reported as:
Mean · ng/mL
Serum Denosumab Trough Levels in Participants Who Received Q3W Dosing
ng/mLDenosumab
Dose 2 - Day 88590 ± 4080
Dose 3 - Week 312200 ± 5710
Dose 4 - Week 619700 ± 7350
Dose 5 - Week 919600 ± 8270
Dose 6 - Week 1222800 ± 10400
Dose 7 - Week 1524300 ± 11500
Dose 8 - Week 1822700 ± 10600
Dose 9 - Week 2122100 ± 11200
Dose 10 - Week 2423300 ± 12700
SecondarySerum Denosumab Trough Levels in Participants Who Received Q4W Dosing

Serum samples were analyzed for denosumab using enzyme-linked immunosorbent assay (ELISA) following a validated procedure. The lower limit of quantification for the assay was 20 ng/mL.

Time frame:
Prior to dosing at day 8 and weeks 4, 8, 12, 16, 20 and 24
Reported as:
Mean · ng/mL
Serum Denosumab Trough Levels in Participants Who Received Q4W Dosing
ng/mLDenosumab
Dose 2 - Day 88990 ± 2470
Dose 3 - Week 410900 ± 3170
Dose 4 - Week 815700 ± 6710
Dose 5 - Week 1214500 ± 4940
Dose 6 - Week 1613000 ± 4380
Dose 7 - Week 2015400 ± 5620
Dose 8 - Week 2415900 ± 7810
SecondaryNumber of Participants With Treatment-emergent Adverse Events

An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant. The event does not necessarily have a causal relationship with study treatment. A serious adverse event is defined as an AE that meets at least 1 of the following criteria * fatal * life threatening * requires in-patient hospitalization or prolongation of existing hospitalization * results in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event Treatment-related AEs include only TEAEs for which the investigator indicated there was a reasonable possibility they may have been caused by study drug. Fatal adverse events include only deaths reported on the Adverse Event Case Report Form.

Time frame:
From first dose of study drug to the end of study date; the median (min, max) duration was 10.0 (0.2, 41.4) and 9.4 (0.2, 42.9) months for Placebo and Denosumab respectively.
Reported as:
Number · participants
Number of Participants With Treatment-emergent Adverse Events
participantsPlaceboDenosumab
All adverse events (AEs)76144
Serious adverse events68129
AEs leading to discontinuation of study drug620
Fatal adverse events53113
Treatment-related adverse events (TRAEs)2451
Treatment-related serious adverse events06
TRAEs leading to discontinuation of study drug07
Treatment-related fatal adverse events00

Adverse events

Collected over From first dose of study drug to the end of study date; the median (min, max) duration was 10.0 (0.2, 41.4) and 9.4 (0.2, 42.9) months for Placebo and Denosumab respectively.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—68/76 (89.5%)71/76 (93.4%)
Denosumab—129/145 (89%)139/145 (95.9%)
Most frequent serious events
Showing 10 of 152
Most frequent serious events
EventPlaceboDenosumab
Non-small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)9/7619/145
DyspnoeaRespiratory, thoracic and mediastinal disorders2/7616/145
PneumoniaInfections and infestations7/7614/145
Non-small cell lung cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)7/7614/145
PyrexiaGeneral disorders2/7612/145
Non-small cell lung cancer stage IVNeoplasms benign, malignant and unspecified (incl cysts and polyps)5/7612/145
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)5/7610/145
AnaemiaBlood and lymphatic system disorders5/765/145
Febrile neutropeniaBlood and lymphatic system disorders5/766/145
ThrombocytopeniaBlood and lymphatic system disorders5/764/145
Most frequent other events
Showing 10 of 64
Most frequent other events
EventPlaceboDenosumab
AnaemiaBlood and lymphatic system disorders38/7660/145
FatigueGeneral disorders33/7667/145
NauseaGastrointestinal disorders34/7664/145
ConstipationGastrointestinal disorders27/7650/145
Decreased appetiteMetabolism and nutrition disorders23/7634/145
VomitingGastrointestinal disorders14/7635/145
DyspnoeaRespiratory, thoracic and mediastinal disorders18/7635/145
Oedema peripheralGeneral disorders17/7626/145
NeutropeniaBlood and lymphatic system disorders15/7632/145
ThrombocytopeniaBlood and lymphatic system disorders16/7616/145

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboDenosumabTotal
Mean64.0 ± 10.163.8 ± 9.763.8 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboDenosumabTotal
Female205474
Male5894152
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboDenosumabTotal
Black or African American279
White or Caucasian73133206
Others3811
Presence of Bone Metastasis
Presence of Bone Metastasis(Participants)PlaceboDenosumabTotal
Yes3565100
No4383126
Histology
Histology(Participants)PlaceboDenosumabTotal
Squamous183553
Non-squamous60113173
Geographic region
Geographic region(Participants)PlaceboDenosumabTotal
North America/Australia306393
Western Europe3567102
Rest of World131831
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)PlaceboDenosumabTotal
0 (Fully active)3369102
1 (Restrictive but ambulatory)4579124
Time from Initial Diagnosis of NSCLC to Randomization
Time from Initial Diagnosis of NSCLC to Randomization(months)PlaceboDenosumabTotal
Mean2.46 ± 5.286.32 ± 16.964.99 ± 14.17
08

Study locations

74 sites
  • Research Site
    Goodyear, Arizona 85338, United States
  • Research Site
    Anaheim, California 92801, United States
  • Research Site
    Long Beach, California 90813, United States
  • Research Site
    Los Angeles, California 90024, United States
  • Research Site
    Los Angeles, California 90048, United States
  • Research Site
    Farmington, Connecticut 06030-1628, United States
  • Research Site
    Alexandria, Louisiana 71301, United States
  • Research Site
    Brewer, Maine 04412, United States
  • Research Site
    Westminster, Maryland 21157, United States
  • Research Site
    Fairhaven, Massachusetts 02719, United States
  • Research Site
    Detroit, Michigan 48202, United States
  • Research Site
    East Setauket, New York 11733, United States
  • Research Site
    Durham, North Carolina 27710, United States
  • Research Site
    Hickory, North Carolina 28602, United States
  • Research Site
    Winston-Salem, North Carolina 27157, United States
  • Research Site
    Bismarck, North Dakota 58501, United States
  • Research Site
    Cincinnati, Ohio 45267, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Kogarah, New South Wales 2217, Australia
  • Research Site
    Wahroonga, New South Wales 2076, Australia
  • Research Site
    Adelaide, South Australia 5000, Australia
  • Research Site
    Footscray, Victoria 3011, Australia
  • Research Site
    Parkville, Victoria 3050, Australia
  • Research Site
    Wodonga, Victoria 3690, Australia
  • Research Site
    Edmonton, Alberta T6G 1Z2, Canada
  • Research Site
    Saint John, New Brunswick E2L 4L2, Canada
  • Research Site
    Kitchener, Ontario N2G 1G3, Canada
  • Research Site
    Sudbury, Ontario P3E 5J1, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Toronto, Ontario M9N 1N8, Canada
  • Research Site
    Montreal, Quebec H2W 1S6, Canada
  • Research Site
    Chomutov, 430 12, Czechia
  • Research Site
    Ostrava-Poruba, 708 52, Czechia
  • Research Site
    Pardubice, 532 03, Czechia
  • Research Site
    Praha 8, 180 81, Czechia
  • Research Site
    Usti nad Labem, 401 13, Czechia
  • Research Site
    Caen Cedex 5, 14076, France
  • Research Site
    Dijon cedex, 21079, France
  • Research Site
    Nantes Cedex 2, 44202, France
  • Research Site
    Paris Cedex 10, 75475, France
  • Research Site
    Paris Cedex 14, 75674, France
  • Research Site
    Paris Cedex 20, 75020, France
  • Research Site
    Pessac Cedex, 33604, France
  • Research Site
    Reims Cedex, 51056, France
  • Research Site
    Saint Quentin, 02321, France
  • Research Site
    Tours Cedex 9, 37044, France
  • Research Site
    Berlin, 14165, Germany
  • Research Site
    Grosshansdorf, 22927, Germany
  • Research Site
    Köln-Merheim, 51109, Germany
  • Research Site
    Ulm, 89081, Germany
  • Research Site
    Athens, 11522, Greece
  • Research Site
    Athens, 12462, Greece
  • Research Site
    Heraklion, 71110, Greece
  • Research Site
    Patra, 26504, Greece
  • Research Site
    Thessaloniki, 54622, Greece
  • Research Site
    Thessaloniki, 57010, Greece
  • Research Site
    Monza (MB), 20900, Italy
  • Research Site
    Orbassano (TO), 10043, Italy
  • Research Site
    Pavia, 27100, Italy
  • Research Site
    Roma, 00128, Italy
  • Research Site
    Saronno VA, 21047, Italy
  • Research Site
    's Hertogenbosch, 5223 GZ, Netherlands
  • Research Site
    Arnhem, 6815 AD, Netherlands
  • Research Site
    Harderwijk, 3844 DG, Netherlands
  • Research Site
    Tilburg, 5022 GC, Netherlands
  • Research Site
    Zutphen, 7207 AE, Netherlands
  • Research Site
    Bristol, BS2 8ED, United Kingdom
  • Research Site
    Exeter, EX2 5DW, United Kingdom
  • Research Site
    Glasgow, G42 9LF, United Kingdom
  • Research Site
    Guildford, GU2 7XX, United Kingdom
  • Research Site
    London, SE1 9RT, United Kingdom
  • Research Site
    London, W6 8RF, United Kingdom
  • Research Site
    Plymouth, PL6 8DH, United Kingdom
  • Research Site
    Preston, PR2 9HT, United Kingdom
09

References and documents

Publications

  • Peters S, Danson S, Ejedepang D, Dafni U, Hasan B, Radcliffe HS, Bustin F, Crequit J, Coate L, Guillot M, Surmont V, Rauch D, Rudzki J, O'Mahony D, Barneto Aranda I, Scherz A, Tsourti Z, Roschitzki-Voser H, Pochesci A, Demonty G, Stahel RA, O'Brien M. Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials. Lung Cancer. 2021 Nov;161:76-85. doi: 10.1016/j.lungcan.2021.09.002. Epub 2021 Sep 9. PubMed 34543941 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2013 to primary completion in Jul 2016, 30 months.

Results were first posted in Aug 2017, 1 year after primary completion.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 30 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2013
First posted
Sep 26, 2013
StartActual
Dec 31, 2013
Primary completionActual
Jul 29, 2016
CompletionActual
Nov 28, 2017
Results first posted
Aug 28, 2017
Last update
Oct 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01951586
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Sep 26, 2013
Start date
Dec 31, 2013
Primary completion
Jul 29, 2016
Completion
Nov 28, 2017
Results posted
Aug 28, 2017
Last update
Oct 25, 2021

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion